We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current CLRB market cap is 92.27M. The company's latest EPS is USD and P/E is N/A.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -7.82M | -7.42M | -8.71M | -8.29M | -9.41M |
| Net Income | -7.81M | -7.22M | -8.58M | -8.22M | -13.73M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14.18M | -15.29M | -24.13M | -28.81M | -38.96M |
| Net Income | -14.09M | -15.09M | -24.12M | -28.6M | -37.98M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 19.32M | 21.59M | 14.84M | 6.51M | 21.55M |
| Total Liabilities | 6.57M | 6.08M | 7.5M | 6.98M | 16.98M |
| Total Equity | 12.75M | 15.51M | 7.33M | -467k | -13.35M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 12.25M | 58.66M | 37.2M | 21.59M | 12.08M |
| Total Liabilities | 3.19M | 3.86M | 4.16M | 6.08M | 13.43M |
| Total Equity | 9.06M | 54.8M | 33.05M | 15.51M | -1.36M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -17.81M | -25.22M | -7.18M | -14.71M | -22.78M |
| Investing | -109k | -226k | N/A | N/A | -597k |
| Financing | N/A | 9.61M | N/A | N/A | 22.5M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -11.69M | -13.93M | -22.57M | -25.22M | -32.38M |
| Investing | -25k | -62k | -141k | -226k | -864k |
| Financing | 9.02M | 60.55M | 1.25M | 9.61M | 22.94M |
| Market Cap | 92.27M |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 30.45M |
| Average Volume (1 week) | 1.05M |
| Average Volume (1 Month) | 993.18k |
| 52 Week Change | 107.53% |
| 52 Week High | 4.45 |
| 52 Week Low | 1.33 |
| Spread (Intraday) | 0.02 (0.66%) |
| Company Name | Cellectar Biosciences Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.cellectar.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
